The FDA granted fast track designation to PAS-004, a macrocyclic MEK inhibitor, for NF1-associated plexiform neurofibromas ...

As treatment options expand in chronic lymphocytic leukemia (CLL), the benefits and limitations of fixed-duration regimens in ...

According to a recent systematic review published in JCO Oncology Practice, implementation of same-day multidisciplinary ...

Dr Thomas Flaig from the University of Colorado Anschutz discusses a paradigm shift in treating urothelial carcinoma patients ...

At the 2026 European Lung Cancer Congress (ELCC), Dr Nicolas Girard discussed updated data from the PALOMA-2 study, which ...

The investigators note that the lower rate of feeding-tube placement with IMPT at the end of treatment, combined with a ...

The Centers for Medicare & Medicaid Services has issued a permanent billing and reimbursement J-code, J9183, for the ...

The FDA granted breakthrough therapy designation to plixorafenib for adult patients with BRAF V600E–mutated high-grade glioma ...

The study investigated r ezatapopt (PC14586), a first-in-class small molecule designed to selectively bind and reactivate the ...

The FDA has granted traditional approval to brexucabtagene autoleucel (Tecartus; brexu-cel) for treatment of adult patients ...

The phase 3 ATOMIC trial is changing the way we treat stage III dMMR colon cancer. In this video, Dr. Sinicrope breaks down ...

The FDA has extended the deadline to review Orca-T for the treatment of myelodsyplastic syndromes and acute leukemias with a ...